TG Therapeutics
TGTX Mid CapHealthcare · Biotechnology
Aggiornato: May 2, 2026, 22:05 UTC
Metriche Chiave
Analisi della Valutazione
Informazioni sull'Azienda
TG Therapeutics Stock at a Glance
TG Therapeutics (TGTX) is currently trading at 28,87 € with a market capitalization of 4,6 Mrd. €. The trailing P/E ratio stands at 12.22x, with a forward P/E of 14.06x. The 52-week range spans from 21,56 € to 34,97 €; the current price is 17.4% below the yearly high. Year-over-year revenue growth stands at +78.0%. The net profit margin stands at 72.56%.
💰 Dividendo
TG Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Raccomandazioni degli Analisti
7 analysts rate TG Therapeutics (TGTX) on consensus: Comprare. The average price target is 38,02 €, implying +31.67% from the current price. Analyst price targets range from 12,80 € to 51,18 €.
Tesi di Investimento: Punti di Forza e Debolezze
- Strong revenue growth of 78% YoY
- Profitable with 72.56% net margin
- High return on equity (102.75% ROE)
- High gross margin of 83.66% — indicates pricing power
- Analyst consensus: Buy
- Currently flagged as undervalued
- Solid balance sheet with low debt (D/E 39.26)
- –High short interest (23.48%)
- –Negative free cash flow
Panoramica Tecnica
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profilo di Rischio
The data points to above-average price swings, elevated short interest (23.48%).
Dati di Trading
Azioni Correlate nello Stesso Settore
Where can I buy TG Therapeutics?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
